Applicant: Ulrike G. Munderloh Attorney's Docket No.: 09531-125US1 / Z02209

Serial No.: 10/524,338
Filed: February 11, 2005
Page: 2 of 7

## Amendments to the Claims:

Please amend claims 1, 7, 8, 20, 26, 29, 30, 31, 40 and 42 as follows. Please cancel claims 2-6, 9-19, 21-25, 27, 32-39, 41 and 43-46 without prejudice to continued prosecution. The claims and their status are shown below

- (Currently Amended) An isolated mammalian cell stably infected with [[an]]
   Anaplasma species selected from the group consisting of A. marginale, A. centrale, A. bovis, A. ovis, and A. platys, wherein said mammalian cell is a nucleated monkey cell.
  - 2-6. (Canceled)
- (Withdrawn—Currently Amended) The isolated mammalian cell of claim 1, wherein said mammalian monkey cell is an endothelial cell.
- (Withdrawn—Currently Amended) The isolated mammalian cell of claim 7, wherein said cell is selected from the group consisting of a bovine corneal endothelial cell, a rhesus monkey microvascular endothelial cell, a human umbilical vascular endothelial cell, and a human microvascular endothelial cell.
  - 9-19. (Canceled)
- 20. (Currently Amended) A method of making a mammalian cell that is stably infected with [[an]] Anaplasma species selected from the group consisting of A. marginale, A. centrale, A. bovis, A. ovis, and A. platys, said method comprising contacting a nucleated mammalian monkey cell with said A. marginale Anaplasma species to produce a mammalian cell stably infected with said A. marginale Anaplasma species.
  - 21-25. (Canceled)
- 26. (Currently Amended) A method for propagating [[an]] Anaplasma species selected from the group consisting of A. marginale, A. centrale, A. bovis, A. ovis, and A. platys; said method comprising contacting a nucleated mammalian monkey cell with said A. marginale Anaplasma species to produce a mammalian monkey cell stably infected with said A. marginale Anaplasma species, and culturing said stably infected mammalian monkey cell.
  - 27. (Canceled)
- 28. (Original) The method of claim 27, wherein said A. marginale is obtained from tick cells or red blood cells.

Attorney's Docket No.: 09531-125US1 / Z02209 Applicant: Ulrike G. Munderloh

Serial No.: 10/524,338 Filed: February 11, 2005

Page : 3 of 7

29. (Currently Amended) The method of claim 26, wherein said mammalian monkey cell is an endothelial cell or a Vero cell.

- 30. (Withdrawn—Currently Amended) The method of claim 29, wherein said mammalian cell is selected from the group consisting of a bovine corneal endothelial cell, a rhesus monkey microvascular endothelial cell, a human umbilical vascular endothelial cell, and a human microvascular endothelial cell.
- 31. (Currently Amended) The method of claim 26, wherein said A. marginale Anaplasma species is propagated for at least 8 weeks.
  - 32-39. (Canceled)
- 40. (Currently Amended) A method for obtaining [[an]] Anaplasma species selected from the group consisting of A. marginale, A. centrale, A. bovis, A. ovis, and A. platys, said method comprising culturing a nucleated mammalian monkey cell stably infected with said A. marginale Anaplasma species, and isolating said A. marginale Anaplasma species from said mammalian monkey cell.
  - 41. (Canceled)
- 42. (Currently Amended) The method of claim 40, wherein said A. marginale Anaplasma species is cultured under conditions in which said A. marginale is [[an]] attenuated Anaplasma species.
  - 43-46. (Canceled)